High dose intramuscular methylprednisolone in experimental Staphylococcus aureus endophthalmitis.
We attempted to determine whether treatment using intramuscular methylprednisolone plus intravitreal vancomycin decreased ocular inflammation and preserved retinal function better in experimental Staphylococcus aureus (S. aureus) endophthalmitis than treatment with intravitreal vancomycin alone. Sixteen rabbits received intravitreal inoculations in both eyes with S. aureus and the rabbits were divided into two groups (group I and group II) of eight rabbits each. Group I rabbits were treated with one injection of intravitreal vancomycin in each eye at either 24, 36, 48 or 72 hours after bacterial inoculation followed by seven consecutive days of high dose intramuscular methylprednisolone (30 mg/kg per day). Group II rabbits were treated with only one intravitreal injection of vancomycin in each eye at equivalent time intervals as in Group I. Clinical evaluations of ocular inflammation were performed by slit-lamp biomicroscopy and indirect ophthalmoscopy. Electroretinography (ERG) was performed eight days after bacterial inoculation to assess retinal function in all eyes. The combination of intramuscular methylprednisolone and intravitreal vancomycin resulted in a degree of ocular inflammation equal to eyes treated with intravitreal vancomycin alone at all treatment intervals. ERG responses were not significantly different in either group. A single intravitreal injection of vancomycin plus daily intramuscular methylprednisolone for seven days were found neither to decrease ocular inflammation nor preserve retinal function better than a single intravitreal injection of vancomycin in our experimental model of S. aureus endophthalmitis.
Jules Stein Eye Institute, UCLA School of Medicine, Department of Ophthalmology, Los Angeles, California 90095-7000, USA.
M O
MO
Yoshizumi
A
A
Kashani
J
J
Palmer
G
G
Lee
B
B
Mondino
D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004596:Electroretinography; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005938:Glucocorticoids / Q000008:administration & dosage*; D007273:Injections, Intramuscular; D008775:Methylprednisolone / Q000008:administration & dosage*; D011817:Rabbits; D012160:Retina / Q000502:physiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000502:physiology; D014640:Vancomycin / Q000627:therapeutic use; D014822:Vitreous Body
D005938:Glucocorticoids; D014640:Vancomycin; D008775:Methylprednisolone